Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies.

导出 OA

翻译打印收藏纠错

第一作者： Risa,Kagan

第一单位： Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, CA and Sutter East Bay Medical Foundation, 2500 Milvia Street, Berkeley, CA, 94704, USA. risa.kagan@sutterhealth.org.

作者： Risa,Kagan ^[1] ; Antonio,Cano ^[2] ; Rossella E,Nappi ^[3] ; Marci L,English ^[4] ; Shayna,Mancuso ^[4] ; Xi,Wu ^[4] ; Faith D,Ottery ^[4]

作者单位： Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, CA and Sutter East Bay Medical Foundation, 2500 Milvia Street, Berkeley, CA, 94704, USA. risa.kagan@sutterhealth.org. ^[1] University of Valencia, Valencia, Spain.;Women's Health Research Group, Health Research Institute INCLIVA, Valencia, Spain. ^[2] University of Pavia, Pavia, Italy.;Research Center for Reproductive Medicine and Gynecological Endocrinology-Menopause Unit, Fondazione Policlinico IRCCS S. Matteo, Pavia, Italy. ^[3] Astellas Pharma Global Development, Northbrook, IL, USA. ^[4]

关键词 52-week safety Endometrial hyperplasia Fezolinetant Neurokinin 3 receptor antagonist Transaminases Treatment-emergent adverse events Vasomotor symptoms